Navigation Links
ThromboGenics and BioInvent Announce a Strategic Alliance With Roche for TB-403, a Novel Anti-Cancer Antibody
Date:6/17/2008

LEUVEN, Belgium, LUND, Sweden and BASEL, Switzerland, June 18 /PRNewswire-FirstCall/ -- ThromboGenics NV (Euronext Brussels: THR) and BioInvent International AB (Nordic Exchange: BINV) announce that they have entered into a license agreement with Roche (SWX: ROG) for their jointly developed anti-cancer agent TB-403. TB-403 is a novel monoclonal antibody which blocks Placental Growth Factor (PIGF), one of the growth factors responsible for the development of new blood vessels.

Under the terms of the agreement effective from June 17, 2008 (or if a U.S. anti-trust clearance is required, from the date of receipt of such clearance), Roche will pay ThromboGenics and BioInvent an upfront payment of EUR50 million. In addition, ThromboGenics and BioInvent could potentially receive up to EUR450 million over the term of the collaboration based on the successful completion of a series of development and commercial milestones for multiple indications, as well as double digit royalties on potential product sales, including any backup antibodies based on inhibition of PlGF. ThromboGenics, which discovered TB-403, will receive 60% and BioInvent 40% of the revenue from the deal. Roche will have a worldwide, exclusive license to develop and commercialize TB-403. ThromboGenics and BioInvent will retain co-promotion rights for the product in the Benelux, Baltic and Nordic regions.

ThromboGenics and BioInvent are responsible for any remaining costs associated with the recently completed Phase Ia trial in healthy volunteers. Roche will assume responsibility for all future development costs for this novel therapy, including the costs of the pending Phase Ib trial in patients to be run by ThromboGenics and BioInvent. ThromboGenics and BioInvent in conjunction with Roche will form a Joint Steering Committee to oversee research and development activities. In addition, Roche will also provide funding to ThromboGenics and BioInvent for research on non-cancer indications an
'/>"/>

SOURCE ThromboGenics NV
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6

Related biology technology :

1. ThromboGenics - Business Update and Interim Results for the Seven Month Period Ending 30 June 2007
2. ThromboGenics Announces Successful Completion of Technology Transfer to Bharat Biotech for Production of Novel Thrombolytic Agent
3. ThromboGenics and BioInvent Announce Successful Completion of Phase I Clinical Trial of the Anticoagulant TB-402
4. ThromboGenics and BioInvent Announce Publication of Exciting Data on a Novel Class of Angiogenesis Inhibitors in Cell
5. ThromboGenics Presents Results of the Vitreomacular Traction Trial (MIVI IIT) at the American Society of Retina Specialists Annual Meeting
6. ThromboGenics Presents Results of the Phase I Trial of TB-402 at the Prestigious American Society of Hematology Annual Meeting
7. ThromboGenics and BioInvent Receive Approval to Begin Clinical Trials of TB-403 for the Treatment of Cancer
8. ThromboGenics Announces 2007 Full Year Results
9. ThromboGenics Completes Patient Enrolment of MITI IV Trial, a Phase II Study Evaluating the Safety and Preliminary Efficacy of Microplasmin in the Treatment of Acute Stroke
10. ThromboGenics N.V. - Business Update
11. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/20/2013)... Biomarkers and Clinigene International are set to unveil their ... 2013 AAPS/ National Biotechnology Conference May 20-22 ... Marina , San Diego, CA. ... company representatives at their collaborative seminar, "Biosimilarity, Immunogenicity and ... 1-2 p.m. in the conference,s Spinnaker Room. ...
(Date:5/20/2013)... HILL, N.C. , May 20, 2013 /PRNewswire/ ... company focused on developing differentiated antibiotics to meet ... infections, today announced that it presented data at ... in Philadelphia demonstrating the ... levofloxacin in Cempra,s prior Phase 2 clinical trial ...
(Date:5/20/2013)... Interventional cardiologist Tony Farah, MD, and his ... Cardiovascular Institute have helped pioneer many breakthroughs in ... over the past three decades, from new disease-fighting medications ... artery stent implantation. , Today, AGH officials announced that ... in the study of a novel, first-of-its kind investigational ...
(Date:5/20/2013)... 2013 On 25-28 July, 2013, UPCP ... Paris - the beautiful city of lights. , According ... is revolutionizing the medical world. Understanding and integrating genetic ... hallmark of this transformation. Much of the present medical ... epidemiologic studies of large cohorts that do not take ...
Breaking Biology Technology:Pacific Biomarkers and Clinigene International To Announce Laboratory Solutions for Developers of Biosimilars at 2013 AAPS/ National Biotechnology Conference 2Cempra Presents Post-Phase 2 Analysis of Solithromycin's Efficacy and Safety Results from Patients with Community Acquired Bacterial Pneumonia (CABP) 2Allegheny General Hospital Cardiovascular Institute Becomes Exclusive Pittsburgh Site for Study of Novel Coronary Artery Disease Device 2Allegheny General Hospital Cardiovascular Institute Becomes Exclusive Pittsburgh Site for Study of Novel Coronary Artery Disease Device 3Allegheny General Hospital Cardiovascular Institute Becomes Exclusive Pittsburgh Site for Study of Novel Coronary Artery Disease Device 4The International Congress on Personalized Medicine - Up Close and Personalized 2013 in Paris 2
... , May 18, 2010 , , ... - With Photo , , , ... safety device is now cleared by FDA for Home/Self use and is,consequently available to all ... dislodgement,during hemodialysis and its use has already improved in-clinic patient,safety. Optimizing safety conditions for home ...
... ... highly specialized metal tubing and innovative suppliers with ultra-fine finishing capabilities , ... (PRWEB) -- The increased miniaturization ... off in many ways. One of the integral items that have helped to ...
... , ... METTLER TOLEDO announced a collaboration to combine their existing technologies to offer flow reactor ... production. , ... (PRWEB) -- ThalesNano and METTLER TOLEDO announced a partnership to offer flow reactor technology ...
Cached Biology Technology:Redsense Medical Receives FDA Clearance for the Redsense Safety Device for Home/Self use During Home Hemodialysis 2Ultra-Fine Metal Tubing Smoothes the Way for Miniaturized Medical Devices 2Ultra-Fine Metal Tubing Smoothes the Way for Miniaturized Medical Devices 3METTLER TOLEDO and ThalesNano Bring Real-time Reaction Monitoring to Flow Synthesis 2METTLER TOLEDO and ThalesNano Bring Real-time Reaction Monitoring to Flow Synthesis 3METTLER TOLEDO and ThalesNano Bring Real-time Reaction Monitoring to Flow Synthesis 4
(Date:5/19/2013)... study reports that white men and women of European ... valgus) and lesser toe deformities, including hammer or claw ... estimate the heritability of foot disorders in humansappear in ... by Wiley on behalf of the American College of ... many as 60% of older adults have foot disorders ...
(Date:5/18/2013)... today at Digestive Disease Week (DDW) explores new discoveries ... of coffee on autoimmune disease and palliative care for ... been associated with reduced risk of fibrosis, a new ... java each month also correlate with lower risk for ... Clinic, Rochester, MN, linked coffee consumption with reduced risk ...
(Date:5/17/2013)... South, but the night belongs to the amphibians. In ... humidity and the sounds of wildlife. , The Southeast, ... salamanders, is the center of amphibian biodiversity in our nation. ... their symphonic choruses, the scientists of the U.S. Geological Survey,s ... , Amphibians, which rely on water for part ...
Breaking Biology News(10 mins):Blame your parents for bunion woes 2Coffee consumption associated with reduced risk of autoimmune liver disease 2Front-row seats to climate change 2Front-row seats to climate change 3Front-row seats to climate change 4
... soon be able to wear contact lenses that continuously ... changing colours replacing the need to routinely draw ... by Chemical and Biochemical Engineering professor Jin Zhang at ... embedded into the hydrogel lenses. These engineered nanoparticles ...
... the deoxycytidine kinase (dCK) enzyme have defects in their ... T and B lymphocytes, the major players involved in ... UCLA,s Jonsson Comprehensive Cancer Center. The finding could ... body attacks itself, and possibly certain cancers of the ...
... common minerals in biology, including those in bones and shells, have ... making them behave as one giant crystal, even though they do ... grains of salt were spilled on a rug, yet instead of ... rotation. In a new study in the Journal ...
Cached Biology News:Enzyme necessary for development of healthy immune system 2Enzyme necessary for development of healthy immune system 3Dental delight: Tooth of sea urchin shows formation of biominerals 2Dental delight: Tooth of sea urchin shows formation of biominerals 3
...
...
BD BioCoat Laminin 60 mm Culture Dishes, tissue-culture treated polystyrene with a uniform application of mouse laminin....
... BD BioCoat Collagen I 60 mm Culture Dishes ... Dishes, tissue-culture treated polystyrene with a uniform application ... Coating : Collagen I ,Surface : ... 21.3 cm2 ,Dim nominal : 60 ...
Biology Products: